Atossa Genetics (NASDAQ:ATOS – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.30, FiscalAI reports.
Atossa Genetics Stock Up 4.5%
Shares of NASDAQ:ATOS traded up $0.10 during trading on Tuesday, reaching $2.23. The stock had a trading volume of 33,170 shares, compared to its average volume of 112,619. The firm has a market capitalization of $22.21 million, a price-to-earnings ratio of -0.72 and a beta of 1.38. Atossa Genetics has a 52 week low of $1.70 and a 52 week high of $14.85. The stock has a fifty day simple moving average of $2.37 and a two-hundred day simple moving average of $3.78.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on ATOS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Atossa Genetics in a research note on Tuesday, September 8th. Wall Street Zen raised shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Atossa Genetics presently has a consensus rating of “Moderate Buy” and an average target price of $20.33.
View Our Latest Analysis on Atossa Genetics
Atossa Genetics Company Profile
Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.
Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
Featured Stories
- Five stocks we like better than Atossa Genetics
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
